The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

Abstract Background The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinediones for peroxisome proliferator-activated recept...

Full description

Bibliographic Details
Main Authors: Charles E. Leonard, Colleen M. Brensinger, Ghadeer K. Dawwas, Rajat Deo, Warren B. Bilker, Samantha E. Soprano, Neil Dhopeshwarkar, James H. Flory, Zachary T. Bloomgarden, Joshua J. Gagne, Christina L. Aquilante, Stephen E. Kimmel, Sean Hennessy
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Cardiovascular Diabetology
Subjects:
Thiazolidinediones
Type 2 diabetes mellitus
Sudden cardiac death
Cardiac arrhythmias
Cohort studies
Pharmacoepidemiology
Online Access:http://link.springer.com/article/10.1186/s12933-020-00999-5

Internet

http://link.springer.com/article/10.1186/s12933-020-00999-5

Similar Items